|
Stories from the dialysis comunity across the globe.
|
|
Biotechnology Reports Biochemical Findings From Phase IIa Study With Hypertension Vaccine CYT006-AngQb (Medical News Today) |
 |
 |
|
Cytos Biotechnology Ltd (SIX:CYTN) announced results from a biochemical analysis from a phase IIa study (study 02) with the vaccine candidate CYT006-AngQb for the treatment of hypertension. CYT006-AngQb has demonstrated in a first phase IIa study (study 01) a significant reduction of the day-time ambulatory blood pressure of -9 / -4 mmHg (systolic/diastolic) vs. read more |
|
|
Japan approves first generic biotech drug (Reuters) |
|
|
|
ZURICH (Reuters) - Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday. read more |
|
Japan approves first generic biotech drug (Reuters via Yahoo! News) |
|
|
|
Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday. read more |
|
|
(AFX UK Focus) 2009-06-25 10:06 UPDATE 2-Japan approves first generic biotech drug (Interactive Investor) |
|
|
|
(AFX UK Focus) 2009-06-25 07:22 UPDATE 1-Japan approves Novartis' generic biotech drug (Interactive Investor) |
|
|
|
ZURICH, June 25 (Reuters) - Japanese regulators have approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday. Somatropin, made by Novartis' generics unit Sandoz, is for treatment of growth hormone deficiency in children and growth disturbance associated with Turner's syndrome or ... read more |
|
|
|
|
<< Start < Prev 3681 3682 3683 3684 3685 3686 3687 3688 3689 3690 Next > End >>
|
|
Page 3690 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
